Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Ovid Therapeutics Inc., 3 years.
Ovid Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −121 | $239.24 | $28,948 |
| Mar 4, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −328 | $240.95 | $79,032 |
| Mar 4, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −324 | $241.68 | $78,304 |
| Mar 4, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −71 | $242.93 | $17,248 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Grant or award | +3,871 | — | — |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −204 | $242.37 | $49,443 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −224 | $243.36 | $54,513 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −151 | $244.41 | $36,906 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −111 | $245.26 | $27,224 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −45 | $246.18 | $11,078 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −4 | $247.35 | $989 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −1 | $248.36 | $248 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −465 | $242.69 | $112,851 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −487 | $243.94 | $118,799 |
| Mar 3, 2025 | Alnylam Pharmaceuticals Inc. | Open-market sale | −219 | $245.30 | $53,721 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.